← All Scilex Holding CO filings

Scilex Holding CO Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
SCLX
Scilex Holding CO
SCHEDULE: Oramed Discloses 4.9% Stake in Scilex Holding Co
Oramed Pharmaceuticals Inc. has disclosed a 4.9% beneficial ownership stake in Scilex Holding Co., primarily through warrants and convertible notes.
NASDAQ
SCLX
Scilex Holding CO
SCHEDULE: Oramed Pharmaceuticals Discloses 9.9% Stake in Scilex
Oramed Pharmaceuticals Inc. has filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Scilex Holding Co.
NASDAQ
SCLX
Scilex Holding CO
SCHEDULE: Oramed Pharmaceuticals Discloses 9.9% Scilex Stake
Oramed Pharmaceuticals Inc. has disclosed a 9.9% beneficial ownership stake in Scilex Holding Co, primarily through exercisable warrants.
NASDAQ
SCLX
Scilex Holding CO
SCHEDULE 13G/A: Oramed Pharmaceuticals Discloses 9.9% Passive Stake in Scilex Holding Company
Oramed Pharmaceuticals Inc. has filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Scilex Holding Company, comprising common stock and exercisable warrants, affirming a passive investment intent.
NASDAQ
SCLX
Scilex Holding CO
SCHEDULE 13G: Oramed Pharmaceuticals Discloses 6.2% Passive Stake in Scilex Holding Company
Oramed Pharmaceuticals Inc. has reported a 6.2% beneficial ownership stake in Scilex Holding Company, comprising common stock and exercisable warrants.